{
    "pmcid": "8232969",
    "qa_pairs": {
        "How do some non-neutralizing antibodies enhance SARS-CoV-2 infection in vitro?": [
            "Through Fc receptor (Fc\u03b3R)-mediated uptake",
            "By directly binding to ACE2",
            "By increasing spike protein expression",
            "Through complement activation"
        ],
        "What did in vivo studies in monkeys and mice reveal about antibody-dependent enhancement (ADE) of SARS-CoV-2?": [
            "ADE did not enhance viral replication or cause significant lung pathology",
            "ADE led to increased viral replication and severe lung pathology",
            "ADE was only observed in monkeys, not in mice",
            "ADE caused significant immune suppression"
        ],
        "What is the primary target of neutralizing antibodies (NAbs) on the SARS-CoV-2 spike protein?": [
            "Receptor-binding domain (RBD)",
            "N-terminal domain (NTD)",
            "S2 subunit",
            "Fusion peptide"
        ],
        "What strategy is suggested for designing nanobody binders to improve neutralization efficacy and reduce ADE risk?": [
            "Targeting multiple distinct epitopes on the spike protein",
            "Focusing solely on the RBD region",
            "Avoiding any interaction with the NTD",
            "Designing nanobodies that only bind to the S2 subunit"
        ],
        "What structural technique was used to reveal distinct binding modes of antibodies to the SARS-CoV-2 spike protein?": [
            "Cryo-electron microscopy (cryo-EM)",
            "X-ray crystallography",
            "Nuclear magnetic resonance (NMR)",
            "Atomic force microscopy (AFM)"
        ]
    }
}